Adderall News and Research

RSS
Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.
Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Impax initiates litigation against Shire over supply of generic Adderall XR

Impax initiates litigation against Shire over supply of generic Adderall XR

USN-DAAT to collect unused, expired prescription and OTC drugs from public

USN-DAAT to collect unused, expired prescription and OTC drugs from public

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Impax Laboratories total revenue for second-quarter 2010 increases to $153.1 million

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

International Dairy Foods Association issues statement on Childhood Obesity Report

International Dairy Foods Association issues statement on Childhood Obesity Report

Cardiome Pharma records $15.5M net income for first-quarter 2010

Cardiome Pharma records $15.5M net income for first-quarter 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Shire reports total revenues of $3,008 million for 2009

Shire reports total revenues of $3,008 million for 2009

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Shire settles ADDERALL XR authorized generic version supply litigation

Shire settles ADDERALL XR authorized generic version supply litigation

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries net sales up 25%

Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm commences KP106 Phase 1 clinical trial for ADHD

Shire settles pending ADDERALL XR litigation with Sandoz

Shire settles pending ADDERALL XR litigation with Sandoz

KemPharm announces nomination of its second pipeline candidate

KemPharm announces nomination of its second pipeline candidate

Placebo effects in caregivers may change behavior of children with ADHD

Placebo effects in caregivers may change behavior of children with ADHD